ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Oligonucleotide Drugs (ONs) Market Research Report 2025
Published Date: February 2025
|
Report Code: QYRE-Auto-3U12932
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Oligonucleotide Drugs ONs Market Research Report 2022
BUY CHAPTERS

Global Oligonucleotide Drugs (ONs) Market Research Report 2025

Code: QYRE-Auto-3U12932
Report
February 2025
Pages:79
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Novartis
Ionis
Nippon Shinyaku
Alnylam
Sarepta Therapeutics
Mina Therapeutics
BioNTech
Moderna, Inc

Oligonucleotide Drugs (ONs) Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Oligonucleotide Drugs (ONs) Market

Oligonucleotide Drugs (ONs) Market

The global market for Oligonucleotide Drugs (ONs) was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Nucleic acid medicines utilize nucleic acid, which refer to substances such as DNA and RNA that control genetic information, as drugs. These allow targeting of molecules such as mRNA and miRNA that cannot be targeted with traditional low molecular weight drugs and antibody medicines, and there is a great expectation for these drugs as next generation pharmaceuticals. Active research is being conducted globally as it is expected to lead to the creation of drugs which were previously intractable.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Oligonucleotide drugs (ONs) represent an emerging class of biopharmaceutical products that have witnessed remarkable development in recent years. The market size has been progressively expanding, with diverse applications spanning gene therapy, oncology, and orphan diseases. ONs have garnered attention for their highly precise mechanisms of action and relatively low risk of adverse effects, leading to the approval of several drugs for clinical use. With continuous advancements in research and technology, the future of oligonucleotide drugs holds promise in further extending their applications to areas like tumor immunotherapy and treatment of genetic disorders, offering patients more precise and effective therapeutic options.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Oligonucleotide Drugs (ONs), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oligonucleotide Drugs (ONs).
The Oligonucleotide Drugs (ONs) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Oligonucleotide Drugs (ONs) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oligonucleotide Drugs (ONs) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Oligonucleotide Drugs (ONs) Market Report

Report Metric Details
Report Name Oligonucleotide Drugs (ONs) Market
CAGR 5%
Segment by Type
Segment by Application
  • Cardiovascular Diseases
  • Hepatitis B
  • Hypertension
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Novartis, Ionis, Nippon Shinyaku, Alnylam, Sarepta Therapeutics, MiNA Therapeutics, BioNTech, Moderna
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Oligonucleotide Drugs (ONs) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Oligonucleotide Drugs (ONs) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Oligonucleotide Drugs (ONs) Market report?

Ans: The main players in the Oligonucleotide Drugs (ONs) Market are Novartis, Ionis, Nippon Shinyaku, Alnylam, Sarepta Therapeutics, MiNA Therapeutics, BioNTech, Moderna

What are the Application segmentation covered in the Oligonucleotide Drugs (ONs) Market report?

Ans: The Applications covered in the Oligonucleotide Drugs (ONs) Market report are Cardiovascular Diseases, Hepatitis B, Hypertension, Other

What are the Type segmentation covered in the Oligonucleotide Drugs (ONs) Market report?

Ans: The Types covered in the Oligonucleotide Drugs (ONs) Market report are ASO, siRNA, Other

Recommended Reports

Oligonucleotide Therapeutics

Genomic Medicine

Oncology Drug Markets

1 Oligonucleotide Drugs (ONs) Market Overview
1.1 Product Definition
1.2 Oligonucleotide Drugs (ONs) by Type
1.2.1 Global Oligonucleotide Drugs (ONs) Market Value Comparison by Type (2024 VS 2031)
1.2.2 ASO
1.2.3 siRNA
1.2.4 Other
1.3 Oligonucleotide Drugs (ONs) by Application
1.3.1 Global Oligonucleotide Drugs (ONs) Market Value by Application (2024 VS 2031)
1.3.2 Cardiovascular Diseases
1.3.3 Hepatitis B
1.3.4 Hypertension
1.3.5 Other
1.4 Global Oligonucleotide Drugs (ONs) Market Size Estimates and Forecasts
1.4.1 Global Oligonucleotide Drugs (ONs) Revenue 2020-2031
1.4.2 Global Oligonucleotide Drugs (ONs) Sales 2020-2031
1.4.3 Global Oligonucleotide Drugs (ONs) Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Oligonucleotide Drugs (ONs) Market Competition by Manufacturers
2.1 Global Oligonucleotide Drugs (ONs) Sales Market Share by Manufacturers (2020-2025)
2.2 Global Oligonucleotide Drugs (ONs) Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Oligonucleotide Drugs (ONs) Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Oligonucleotide Drugs (ONs), Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Oligonucleotide Drugs (ONs), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Oligonucleotide Drugs (ONs), Product Type & Application
2.7 Global Key Manufacturers of Oligonucleotide Drugs (ONs), Date of Enter into This Industry
2.8 Global Oligonucleotide Drugs (ONs) Market Competitive Situation and Trends
2.8.1 Global Oligonucleotide Drugs (ONs) Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Oligonucleotide Drugs (ONs) Players Market Share by Revenue
2.8.3 Global Oligonucleotide Drugs (ONs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Oligonucleotide Drugs (ONs) Market Scenario by Region
3.1 Global Oligonucleotide Drugs (ONs) Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Oligonucleotide Drugs (ONs) Sales by Region: 2020-2031
3.2.1 Global Oligonucleotide Drugs (ONs) Sales by Region: 2020-2025
3.2.2 Global Oligonucleotide Drugs (ONs) Sales by Region: 2026-2031
3.3 Global Oligonucleotide Drugs (ONs) Revenue by Region: 2020-2031
3.3.1 Global Oligonucleotide Drugs (ONs) Revenue by Region: 2020-2025
3.3.2 Global Oligonucleotide Drugs (ONs) Revenue by Region: 2026-2031
3.4 North America Oligonucleotide Drugs (ONs) Market Facts & Figures by Country
3.4.1 North America Oligonucleotide Drugs (ONs) Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Oligonucleotide Drugs (ONs) Sales by Country (2020-2031)
3.4.3 North America Oligonucleotide Drugs (ONs) Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Oligonucleotide Drugs (ONs) Market Facts & Figures by Country
3.5.1 Europe Oligonucleotide Drugs (ONs) Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Oligonucleotide Drugs (ONs) Sales by Country (2020-2031)
3.5.3 Europe Oligonucleotide Drugs (ONs) Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Oligonucleotide Drugs (ONs) Market Facts & Figures by Region
3.6.1 Asia Pacific Oligonucleotide Drugs (ONs) Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Oligonucleotide Drugs (ONs) Sales by Region (2020-2031)
3.6.3 Asia Pacific Oligonucleotide Drugs (ONs) Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Oligonucleotide Drugs (ONs) Market Facts & Figures by Country
3.7.1 Latin America Oligonucleotide Drugs (ONs) Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Oligonucleotide Drugs (ONs) Sales by Country (2020-2031)
3.7.3 Latin America Oligonucleotide Drugs (ONs) Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Oligonucleotide Drugs (ONs) Market Facts & Figures by Country
3.8.1 Middle East and Africa Oligonucleotide Drugs (ONs) Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Oligonucleotide Drugs (ONs) Sales by Country (2020-2031)
3.8.3 Middle East and Africa Oligonucleotide Drugs (ONs) Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Oligonucleotide Drugs (ONs) Sales by Type (2020-2031)
4.1.1 Global Oligonucleotide Drugs (ONs) Sales by Type (2020-2025)
4.1.2 Global Oligonucleotide Drugs (ONs) Sales by Type (2026-2031)
4.1.3 Global Oligonucleotide Drugs (ONs) Sales Market Share by Type (2020-2031)
4.2 Global Oligonucleotide Drugs (ONs) Revenue by Type (2020-2031)
4.2.1 Global Oligonucleotide Drugs (ONs) Revenue by Type (2020-2025)
4.2.2 Global Oligonucleotide Drugs (ONs) Revenue by Type (2026-2031)
4.2.3 Global Oligonucleotide Drugs (ONs) Revenue Market Share by Type (2020-2031)
4.3 Global Oligonucleotide Drugs (ONs) Price by Type (2020-2031)
5 Segment by Application
5.1 Global Oligonucleotide Drugs (ONs) Sales by Application (2020-2031)
5.1.1 Global Oligonucleotide Drugs (ONs) Sales by Application (2020-2025)
5.1.2 Global Oligonucleotide Drugs (ONs) Sales by Application (2026-2031)
5.1.3 Global Oligonucleotide Drugs (ONs) Sales Market Share by Application (2020-2031)
5.2 Global Oligonucleotide Drugs (ONs) Revenue by Application (2020-2031)
5.2.1 Global Oligonucleotide Drugs (ONs) Revenue by Application (2020-2025)
5.2.2 Global Oligonucleotide Drugs (ONs) Revenue by Application (2026-2031)
5.2.3 Global Oligonucleotide Drugs (ONs) Revenue Market Share by Application (2020-2031)
5.3 Global Oligonucleotide Drugs (ONs) Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Company Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Oligonucleotide Drugs (ONs) Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Novartis Oligonucleotide Drugs (ONs) Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Ionis
6.2.1 Ionis Company Information
6.2.2 Ionis Description and Business Overview
6.2.3 Ionis Oligonucleotide Drugs (ONs) Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Ionis Oligonucleotide Drugs (ONs) Product Portfolio
6.2.5 Ionis Recent Developments/Updates
6.3 Nippon Shinyaku
6.3.1 Nippon Shinyaku Company Information
6.3.2 Nippon Shinyaku Description and Business Overview
6.3.3 Nippon Shinyaku Oligonucleotide Drugs (ONs) Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Nippon Shinyaku Oligonucleotide Drugs (ONs) Product Portfolio
6.3.5 Nippon Shinyaku Recent Developments/Updates
6.4 Alnylam
6.4.1 Alnylam Company Information
6.4.2 Alnylam Description and Business Overview
6.4.3 Alnylam Oligonucleotide Drugs (ONs) Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Alnylam Oligonucleotide Drugs (ONs) Product Portfolio
6.4.5 Alnylam Recent Developments/Updates
6.5 Sarepta Therapeutics
6.5.1 Sarepta Therapeutics Company Information
6.5.2 Sarepta Therapeutics Description and Business Overview
6.5.3 Sarepta Therapeutics Oligonucleotide Drugs (ONs) Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Sarepta Therapeutics Oligonucleotide Drugs (ONs) Product Portfolio
6.5.5 Sarepta Therapeutics Recent Developments/Updates
6.6 MiNA Therapeutics
6.6.1 MiNA Therapeutics Company Information
6.6.2 MiNA Therapeutics Description and Business Overview
6.6.3 MiNA Therapeutics Oligonucleotide Drugs (ONs) Sales, Revenue and Gross Margin (2020-2025)
6.6.4 MiNA Therapeutics Oligonucleotide Drugs (ONs) Product Portfolio
6.6.5 MiNA Therapeutics Recent Developments/Updates
6.7 BioNTech
6.7.1 BioNTech Company Information
6.7.2 BioNTech Description and Business Overview
6.7.3 BioNTech Oligonucleotide Drugs (ONs) Sales, Revenue and Gross Margin (2020-2025)
6.7.4 BioNTech Oligonucleotide Drugs (ONs) Product Portfolio
6.7.5 BioNTech Recent Developments/Updates
6.8 Moderna
6.8.1 Moderna Company Information
6.8.2 Moderna Description and Business Overview
6.8.3 Moderna Oligonucleotide Drugs (ONs) Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Moderna Oligonucleotide Drugs (ONs) Product Portfolio
6.8.5 Moderna Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Oligonucleotide Drugs (ONs) Industry Chain Analysis
7.2 Oligonucleotide Drugs (ONs) Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Oligonucleotide Drugs (ONs) Production Mode & Process Analysis
7.4 Oligonucleotide Drugs (ONs) Sales and Marketing
7.4.1 Oligonucleotide Drugs (ONs) Sales Channels
7.4.2 Oligonucleotide Drugs (ONs) Distributors
7.5 Oligonucleotide Drugs (ONs) Customer Analysis
8 Oligonucleotide Drugs (ONs) Market Dynamics
8.1 Oligonucleotide Drugs (ONs) Industry Trends
8.2 Oligonucleotide Drugs (ONs) Market Drivers
8.3 Oligonucleotide Drugs (ONs) Market Challenges
8.4 Oligonucleotide Drugs (ONs) Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Novartis
Ionis
Nippon Shinyaku
Alnylam
Sarepta Therapeutics
Mina Therapeutics
BioNTech
Moderna, Inc
List of Tables
 Table 1. Global Oligonucleotide Drugs (ONs) Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Oligonucleotide Drugs (ONs) Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Oligonucleotide Drugs (ONs) Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Oligonucleotide Drugs (ONs) Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Oligonucleotide Drugs (ONs) Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Oligonucleotide Drugs (ONs) Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Oligonucleotide Drugs (ONs) Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Oligonucleotide Drugs (ONs) Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Oligonucleotide Drugs (ONs), Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Oligonucleotide Drugs (ONs), Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Oligonucleotide Drugs (ONs), Product Type & Application
 Table 12. Global Key Manufacturers of Oligonucleotide Drugs (ONs), Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Oligonucleotide Drugs (ONs) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Drugs (ONs) as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Oligonucleotide Drugs (ONs) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Oligonucleotide Drugs (ONs) Sales by Region (2020-2025) & (K Units)
 Table 18. Global Oligonucleotide Drugs (ONs) Sales Market Share by Region (2020-2025)
 Table 19. Global Oligonucleotide Drugs (ONs) Sales by Region (2026-2031) & (K Units)
 Table 20. Global Oligonucleotide Drugs (ONs) Sales Market Share by Region (2026-2031)
 Table 21. Global Oligonucleotide Drugs (ONs) Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Oligonucleotide Drugs (ONs) Revenue Market Share by Region (2020-2025)
 Table 23. Global Oligonucleotide Drugs (ONs) Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Oligonucleotide Drugs (ONs) Revenue Market Share by Region (2026-2031)
 Table 25. North America Oligonucleotide Drugs (ONs) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Oligonucleotide Drugs (ONs) Sales by Country (2020-2025) & (K Units)
 Table 27. North America Oligonucleotide Drugs (ONs) Sales by Country (2026-2031) & (K Units)
 Table 28. North America Oligonucleotide Drugs (ONs) Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Oligonucleotide Drugs (ONs) Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Oligonucleotide Drugs (ONs) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Oligonucleotide Drugs (ONs) Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Oligonucleotide Drugs (ONs) Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Oligonucleotide Drugs (ONs) Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Oligonucleotide Drugs (ONs) Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Oligonucleotide Drugs (ONs) Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Oligonucleotide Drugs (ONs) Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Oligonucleotide Drugs (ONs) Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Oligonucleotide Drugs (ONs) Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Oligonucleotide Drugs (ONs) Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Oligonucleotide Drugs (ONs) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Oligonucleotide Drugs (ONs) Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Oligonucleotide Drugs (ONs) Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Oligonucleotide Drugs (ONs) Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Oligonucleotide Drugs (ONs) Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Oligonucleotide Drugs (ONs) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Oligonucleotide Drugs (ONs) Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Oligonucleotide Drugs (ONs) Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Oligonucleotide Drugs (ONs) Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Oligonucleotide Drugs (ONs) Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Oligonucleotide Drugs (ONs) Sales (K Units) by Type (2020-2025)
 Table 51. Global Oligonucleotide Drugs (ONs) Sales (K Units) by Type (2026-2031)
 Table 52. Global Oligonucleotide Drugs (ONs) Sales Market Share by Type (2020-2025)
 Table 53. Global Oligonucleotide Drugs (ONs) Sales Market Share by Type (2026-2031)
 Table 54. Global Oligonucleotide Drugs (ONs) Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Oligonucleotide Drugs (ONs) Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Oligonucleotide Drugs (ONs) Revenue Market Share by Type (2020-2025)
 Table 57. Global Oligonucleotide Drugs (ONs) Revenue Market Share by Type (2026-2031)
 Table 58. Global Oligonucleotide Drugs (ONs) Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Oligonucleotide Drugs (ONs) Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Oligonucleotide Drugs (ONs) Sales (K Units) by Application (2020-2025)
 Table 61. Global Oligonucleotide Drugs (ONs) Sales (K Units) by Application (2026-2031)
 Table 62. Global Oligonucleotide Drugs (ONs) Sales Market Share by Application (2020-2025)
 Table 63. Global Oligonucleotide Drugs (ONs) Sales Market Share by Application (2026-2031)
 Table 64. Global Oligonucleotide Drugs (ONs) Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Oligonucleotide Drugs (ONs) Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Oligonucleotide Drugs (ONs) Revenue Market Share by Application (2020-2025)
 Table 67. Global Oligonucleotide Drugs (ONs) Revenue Market Share by Application (2026-2031)
 Table 68. Global Oligonucleotide Drugs (ONs) Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Oligonucleotide Drugs (ONs) Price (US$/Unit) by Application (2026-2031)
 Table 70. Novartis Company Information
 Table 71. Novartis Description and Business Overview
 Table 72. Novartis Oligonucleotide Drugs (ONs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Novartis Oligonucleotide Drugs (ONs) Product
 Table 74. Novartis Recent Developments/Updates
 Table 75. Ionis Company Information
 Table 76. Ionis Description and Business Overview
 Table 77. Ionis Oligonucleotide Drugs (ONs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Ionis Oligonucleotide Drugs (ONs) Product
 Table 79. Ionis Recent Developments/Updates
 Table 80. Nippon Shinyaku Company Information
 Table 81. Nippon Shinyaku Description and Business Overview
 Table 82. Nippon Shinyaku Oligonucleotide Drugs (ONs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Nippon Shinyaku Oligonucleotide Drugs (ONs) Product
 Table 84. Nippon Shinyaku Recent Developments/Updates
 Table 85. Alnylam Company Information
 Table 86. Alnylam Description and Business Overview
 Table 87. Alnylam Oligonucleotide Drugs (ONs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Alnylam Oligonucleotide Drugs (ONs) Product
 Table 89. Alnylam Recent Developments/Updates
 Table 90. Sarepta Therapeutics Company Information
 Table 91. Sarepta Therapeutics Description and Business Overview
 Table 92. Sarepta Therapeutics Oligonucleotide Drugs (ONs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Sarepta Therapeutics Oligonucleotide Drugs (ONs) Product
 Table 94. Sarepta Therapeutics Recent Developments/Updates
 Table 95. MiNA Therapeutics Company Information
 Table 96. MiNA Therapeutics Description and Business Overview
 Table 97. MiNA Therapeutics Oligonucleotide Drugs (ONs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. MiNA Therapeutics Oligonucleotide Drugs (ONs) Product
 Table 99. MiNA Therapeutics Recent Developments/Updates
 Table 100. BioNTech Company Information
 Table 101. BioNTech Description and Business Overview
 Table 102. BioNTech Oligonucleotide Drugs (ONs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. BioNTech Oligonucleotide Drugs (ONs) Product
 Table 104. BioNTech Recent Developments/Updates
 Table 105. Moderna Company Information
 Table 106. Moderna Description and Business Overview
 Table 107. Moderna Oligonucleotide Drugs (ONs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Moderna Oligonucleotide Drugs (ONs) Product
 Table 109. Moderna Recent Developments/Updates
 Table 110. Key Raw Materials Lists
 Table 111. Raw Materials Key Suppliers Lists
 Table 112. Oligonucleotide Drugs (ONs) Distributors List
 Table 113. Oligonucleotide Drugs (ONs) Customers List
 Table 114. Oligonucleotide Drugs (ONs) Market Trends
 Table 115. Oligonucleotide Drugs (ONs) Market Drivers
 Table 116. Oligonucleotide Drugs (ONs) Market Challenges
 Table 117. Oligonucleotide Drugs (ONs) Market Restraints
 Table 118. Research Programs/Design for This Report
 Table 119. Key Data Information from Secondary Sources
 Table 120. Key Data Information from Primary Sources
 Table 121. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Oligonucleotide Drugs (ONs)
 Figure 2. Global Oligonucleotide Drugs (ONs) Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Oligonucleotide Drugs (ONs) Market Share by Type: 2024 & 2031
 Figure 4. ASO Product Picture
 Figure 5. siRNA Product Picture
 Figure 6. Other Product Picture
 Figure 7. Global Oligonucleotide Drugs (ONs) Market Value by Application (2020-2031) & (US$ Million)
 Figure 8. Global Oligonucleotide Drugs (ONs) Market Share by Application: 2024 & 2031
 Figure 9. Cardiovascular Diseases
 Figure 10. Hepatitis B
 Figure 11. Hypertension
 Figure 12. Other
 Figure 13. Global Oligonucleotide Drugs (ONs) Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Oligonucleotide Drugs (ONs) Market Size (2020-2031) & (US$ Million)
 Figure 15. Global Oligonucleotide Drugs (ONs) Sales (2020-2031) & (K Units)
 Figure 16. Global Oligonucleotide Drugs (ONs) Average Price (US$/Unit) & (2020-2031)
 Figure 17. Oligonucleotide Drugs (ONs) Report Years Considered
 Figure 18. Oligonucleotide Drugs (ONs) Sales Share by Manufacturers in 2024
 Figure 19. Global Oligonucleotide Drugs (ONs) Revenue Share by Manufacturers in 2024
 Figure 20. Global 5 and 10 Largest Oligonucleotide Drugs (ONs) Players: Market Share by Revenue in Oligonucleotide Drugs (ONs) in 2024
 Figure 21. Oligonucleotide Drugs (ONs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 22. Global Oligonucleotide Drugs (ONs) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 23. North America Oligonucleotide Drugs (ONs) Sales Market Share by Country (2020-2031)
 Figure 24. North America Oligonucleotide Drugs (ONs) Revenue Market Share by Country (2020-2031)
 Figure 25. United States Oligonucleotide Drugs (ONs) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Canada Oligonucleotide Drugs (ONs) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. Europe Oligonucleotide Drugs (ONs) Sales Market Share by Country (2020-2031)
 Figure 28. Europe Oligonucleotide Drugs (ONs) Revenue Market Share by Country (2020-2031)
 Figure 29. Germany Oligonucleotide Drugs (ONs) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. France Oligonucleotide Drugs (ONs) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. U.K. Oligonucleotide Drugs (ONs) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Italy Oligonucleotide Drugs (ONs) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Russia Oligonucleotide Drugs (ONs) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Asia Pacific Oligonucleotide Drugs (ONs) Sales Market Share by Region (2020-2031)
 Figure 35. Asia Pacific Oligonucleotide Drugs (ONs) Revenue Market Share by Region (2020-2031)
 Figure 36. China Oligonucleotide Drugs (ONs) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Japan Oligonucleotide Drugs (ONs) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. South Korea Oligonucleotide Drugs (ONs) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. India Oligonucleotide Drugs (ONs) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Australia Oligonucleotide Drugs (ONs) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. China Taiwan Oligonucleotide Drugs (ONs) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Southeast Asia Oligonucleotide Drugs (ONs) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Latin America Oligonucleotide Drugs (ONs) Sales Market Share by Country (2020-2031)
 Figure 44. Latin America Oligonucleotide Drugs (ONs) Revenue Market Share by Country (2020-2031)
 Figure 45. Mexico Oligonucleotide Drugs (ONs) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Brazil Oligonucleotide Drugs (ONs) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Argentina Oligonucleotide Drugs (ONs) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Middle East and Africa Oligonucleotide Drugs (ONs) Sales Market Share by Country (2020-2031)
 Figure 49. Middle East and Africa Oligonucleotide Drugs (ONs) Revenue Market Share by Country (2020-2031)
 Figure 50. Turkey Oligonucleotide Drugs (ONs) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Saudi Arabia Oligonucleotide Drugs (ONs) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. UAE Oligonucleotide Drugs (ONs) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Global Sales Market Share of Oligonucleotide Drugs (ONs) by Type (2020-2031)
 Figure 54. Global Revenue Market Share of Oligonucleotide Drugs (ONs) by Type (2020-2031)
 Figure 55. Global Oligonucleotide Drugs (ONs) Price (US$/Unit) by Type (2020-2031)
 Figure 56. Global Sales Market Share of Oligonucleotide Drugs (ONs) by Application (2020-2031)
 Figure 57. Global Revenue Market Share of Oligonucleotide Drugs (ONs) by Application (2020-2031)
 Figure 58. Global Oligonucleotide Drugs (ONs) Price (US$/Unit) by Application (2020-2031)
 Figure 59. Oligonucleotide Drugs (ONs) Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Leap India

SIMILAR REPORTS

Global Nucleic Acid Medicine Market Research Report 2025
Global Oligonucleotide Oligo Drugs Market Research Report 2024
Global Antisense oligonucleotides ASO Drug and siRNA Drug Market Research Report 2024
Global Antisense Oligonucleotides ASO Drug Market Research Report 2024
Oligonucleotide Therapeutics Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Low Molecular Weight Nucleic Acid Drugs Market Research Report 2025
Antisense and RNAi Therapeutics Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Nucleic Acid Drugs Market Research Report 2025
Global Oligonucleotide Therapeutics Market Research Report 2024
Global Peptide and Oligonucleotide Drugs Market Research Report 2024
Global ASO based Drug Market Research Report 2024
Global Nucleic Acid Drug Raw Materials Market Research Report 2025
Global Small Nucleic Acid Based Drug Market Research Report 2025
Global Antisense Oligonucleotides ASO Therapy Market Research Report 2024
Small Molecule Nucleic Acid Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Nucleic Acid based Drugs Market Research Report 2024
Global Antisense Oligonucleotide Therapy for the Nervous System Market Research Report 2024
Global Antisense Oligonucleotides based Therapeutics Market Research Report 2024
Global Oligonucleotide Drug Carriers Market Research Report 2024
Global RNA based Therapeutics Drug Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions